Recent Finacing
Recent Raise
Immunocore develops T cell receptor–based ImmTAC/ImmTAX biologics to treat cancer, infectious and autoimmune diseases, advancing multiple clinical-stage programs (including tebentafusp) and partnering with major pharma.
Focus Areas
Recent Investors
Valuation as of 03/02/2020
Total Raised
Funding rounds
Investors
See the team members at Immunocore.
